
## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

## SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

	the Regi a Party o		] in the Registrant [ ]
Check t [ ] [ ] [ ] [ X] [ ]	the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Under § 240.14a-12		
			Bellerophon Therapeutics, Inc. (Name of Registrant as Specified In Its Charter)
		(	(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):  [X] No fee required.  [] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.			
	1)	Title of	each class of securities to which transaction applies:
	2)	Aggrega	ate number of securities to which transaction applies:
	3)		price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set amount on which the filing fee is calculated and state how it was determined):
	4)	Proposed maximum aggregate value of transaction:	
	5)	Total fee	e paid:
[] Ch wh	the paid previously with preliminary materials. The previous files as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for much the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or Schedule and the date of its filing:		
		1)	Amount previously paid:
		2)	Form, Schedule or Registration Statement No:
		3)	Filing party:
		4)	Date Filed:



2 N O T

O3TDCD

COY

## **Shareholder Meeting Notice**

Bellerophon Therapeutics, Inc.'s Annual Meeting of Shareholders will be held on Wednesday, June 7, 2023 at 20 Independence Boulevard, Suite 402, Warren, NJ 07059 at 10:00 a.m. Eastern Time.

Proposals to be voted on at the meeting are listed below along with the Board of Directors' recommendations.

The Board of Directors recommends a vote FOR the nominees listed and FOR Proposal 2, 3 and 4:

- 1. Election of Directors:
  - 01 Scott Bruder
  - 02 Naseem Amin
  - 03 Ted Wang
- 2. To ratify the selection of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023.
- 3. To approve a proposed amendment to the 2015 Equity Incentive Plan, or the 2015 Plan, to increase the aggregate number of authorized shares of common stock, par value \$0.01 per share, reserved for issuance under the 2015 Plan from 833,333 to 1,443,318.
- 4. To approve by an advisory vote the compensation of our named executive officers.

PLEASE NOTE – YOU CANNOT YOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you.



## Here's how to order a copy of the proxy materials and select delivery preferences:

Current and future delivery requests can be submitted using the options below.

If you request an email copy, you will receive an email with a link to the current meeting materials.

PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.

- Internet Go to www.envisionreports.com/BLPH. Click Cast Your Vote or Request Materials.
- Phone Call us free of charge at 1-866-641-4276.
- Email Send an email to investorvote@computershare.com with "Proxy Materials Bellerophon Therapeutics, Inc." in the subject line.
   Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.

To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 24, 2023.